Skip to main content
. 2021 Mar 17;12:1714. doi: 10.1038/s41467-021-21976-w

Fig. 1. TGF-β enriched in the bone induces acetylation of KLF5 at K369.

Fig. 1

a, b IHC staining of Ac-KLF5 and KLF5 in subcutaneous and tibial tumors of PC-3 cells (a) and DU 145 cells (b) from mice treated with the SD-208 TGF-β inhibitor (50 mg/kg/day). Scale bars, 50 μm. c–f Statistical analysis of the IHC images in a and b by calculating the percentages of Ac-KLF5 (c, e) or KLF5 (d, f) positive cells in subcutaneous and tibial tumors of PC-3 (c, d) or DU 145 (e, f) cells, as counted by Fiji software. For each condition in c–f, three tumors from three mice were used, and n = 18 different images from the three tumors were analyzed, except for Ac-KLF5 in subcutaneous PC-3 and DU 145 tumors and tibial DU 145 tumors, where n = 12 different images were used. Scatter bars in black indicate subcutaneous tumors and those in brown indicate tibial tumors. g–i Detection of indicated proteins by western blotting in whole cell lysates of TGF-β treated PC-3 (g), DU 145 (h), and C4-2B (i) cells in in vitro two-dimentional culture. The ratio of Ac-KLF5 to total KLF5 is indicated below the blots. Western blotting assays were repeated at least twice and consistent results were achieved as shown in Supplementary Fig. 1j. In panels c–f, data are shown in mean ± S.E.M. *p < 0.05; **p < 0.01; ***p < 0.001; NS not significant (two-tailed Student’s t test). Source data are provided as a Source Data file.